Search the Newsreel

Pulmatrix Inc (PULM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pulmatrix Inc (PULM), listing its major institutional holders and their respective proportionate holdings. Key institutional shareholders include Renaissance Technologies LLC, BlackRock Institutional Trust Company, N.A., and Geode Capital Management, L.L.C. The report also provides a historical overview …

Pulmatrix, Inc. Revenue Breakdown – NASDAQ:PULM

This article provides a brief overview of Pulmatrix, Inc. with its NASDAQ stock symbol PULM. It focuses on the company's financial data, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub rather than a detailed financial report.

Pulmonx Corp (LUNG) Cash Flow

This article provides a detailed cash flow statement for Pulmonx Corp (LUNG), including operating, investing, and financing cash flows presented quarterly and annually. It outlines key financial metrics and offers definitions for different types of cash flow, along with Pulmonx Corp's specific figures for …

Pulmonx (LUNG) Q1 2026 Earnings: Narrow EPS Beat Sends Stock Lower by 4.1% - CEO Earnings Statement

Pulmonx Corp (LUNG) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Pulmonx Corp (LUNG), noting its current financial score of 6.77, ranking 133rd in the Healthcare Equipment & Supplies industry. It highlights a stable financial status but low operating efficiency, with recent quarterly revenue decreasing by 8.66% …

PULM|Pulmatrix Inc|Price:1.650|

Pulmatrix Inc (PULM) is a biopharmaceutical company focused on developing inhaled therapeutic products for respiratory and CNS diseases using its iSPERSE technology. The company's stock shows healthy fundamentals and high growth potential, though its market activity is low. The stock is currently trading sideways, …

Pulmonx Corp (LUNG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Pulmonx Corp (LUNG), focusing on its regional revenue contributions. As of the specified date, the company has not yet disclosed detailed data for business segments or specific quarterly financial years. The primary revenue source is the United …

Pulmonx Corp (LUNG) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulmonx Corp (LUNG) focusing on its dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years, indicating no recent payouts. The article includes current stock pricing and market …

TradingKey

This article provides a detailed quarterly and annual income statement for Pulmonx Corp (LUNG), offering financial insights into its revenue, operating expenses, and net income. It also includes frequently asked questions about interpreting income statements and key metrics for analyzing LUNG stock. The data …

Pulmonx Corp (LUNG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Pulmonx Corp (LUNG), noting its current valuation score of 7.71, which ranks 138 out of 200 in the Healthcare Equipment & Supplies industry. The company's P/E ratio is reported as -0.91, and other key valuation metrics like …

LUNG|Pulmonx Corp|Price:1.220|Chg%:+0.010

Pulmonx Corp (LUNG) closed at 1.170 USD, down 4.10%. The company, a commercial-stage medical technology firm specializing in COPD treatments, shows strong fundamentals and significant growth potential despite a recent weak stock market performance. Analysts rate it a "Buy" with a target price of …

Pulmatrix Inc. (PULM) Q2 2025 Earnings: EPS of -$0.42 Reported; Stock Climbs 4.97% - Margin Compression Risk

Pulmonx Sets July 29 Webcast to Discuss Second-Quarter Results

Pulmonx Q1 2026 Earnings: EPS Beat Drives 7.55% Stock Surge - Trough Earnings Signal

LUNG Q1 2026 Earnings: EPS Beats Estimates by Narrow Margin, Shares Rise - Book Value Growth

LUNG Q1 2026 Earnings: Adjusted Loss Narrows Slightly, Stock Declines Post-Release - Book Value Growth

Pulmonx Corp 1Q 2026: Revenue $20.59M, EPS ($0.33) — 10-Q Summary

Pulmonx Corporation (LUNG) Stock Falls on Q1 2026 Earnings

Pulmonx Corporation (LUNG) Releases Q4 2025 Earnings: Revenue Down, Diluted Loss Per Share Widens

Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%

Pulmonx Corporation Announces Leadership Transition and Preliminary Third Quarter 2025 Revenue Estimates